TY - JOUR T1 - Prediction of survival for severe Covid-19 patients with three clinical features: development of a machine learning-based prognostic model with clinical data in Wuhan JF - medRxiv DO - 10.1101/2020.02.27.20028027 SP - 2020.02.27.20028027 AU - Li Yan AU - Hai-Tao Zhang AU - Yang Xiao AU - Maolin Wang AU - Chuan Sun AU - Jing Liang AU - Shusheng Li AU - Mingyang Zhang AU - Yuqi Guo AU - Ying Xiao AU - Xiuchuan Tang AU - Haosen Cao AU - Xi Tan AU - Niannian Huang AU - Bo Jiao AU - Ailin Luo AU - Zhiguo Cao AU - Hui Xu AU - Ye Yuan Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/01/2020.02.27.20028027.abstract N2 - The swift spread of COVID-19 epidemic has attracted worldwide attentions since Dec., 2019. Till date, 77,041 confirmed Chinese cases have been reported by National Health Commission of P.R. China with 9,126 critical cases whose survival rate is quite low. Meanwhile, COVID-19 epidemic emergence within the other countries (e.g., Korea, Italy, Japan and Iran) is also remarkable with the increasing spread speed. It plays a more and more important role to efficiently and precisely predict the survival rate for critically ill Covid-19 patients as more fatal cases can be targeted interfered in advanced. However, the survival rates of all the present critically ill COVID -19 patients are estimated manually from over 300 laboratory and clinical features, which inevitably leads to high misdiagnose and missed-diagnose rate due to lack of experience and priori knowledge. As a remedy, we have developed a machine learning-based prognostic model that precisely predicts the survival for individual severe patients with more than 90% accuracy with clinical data collected from Tongji hospital, Wuhan. Significantly, such model only requires three key clinical features, i.e., lactic dehydrogenase (LDH), lymphocyte and High-sensitivity C-reactive protein (hsCRP) out of all 300+ features. The rationality of such mere three features may lie in that they are the representatives of tissue injury-, immunity- and inflammation-typed indices, respectively. From the COVID-19 patient diagnosis aspect, the work actualizes low-cost and prompt criticality classification and survival prediction before targeted intervening and diagnosis, especially for the triage of the large-scale explosive epidemic COVID -19 cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available once the paper gets accepted. The Python code is available upon request from YY. ER -